Daniel Soland has served as a member of DBV’s Board of Directors since 2015. Mr. Soland most recently served as Senior Vice President and Chief Operating Officer of Viropharma, and currently serves on the Board of Directors of Tarsa Therapeutics. Mr. Soland previously served as President of Chiron Vaccines, and helped engineer a turnaround that contributed to the acquisition of Chiron by Novartis. Prior to that, he was President and Chief Executive Officer of Epigenesis Pharmaceuticals and also served as CEO, uniQure. At GlaxoSmithKline Biologicals, Mr. Soland served as Vice President and Director, Worldwide Marketing Operations. Earlier in his career, Mr. Soland held positions of increasing responsibility in sales and product management at Pasteur-Merieux’s Connaught Laboratories. He holds a B.S. in Pharmacy from the University of Iowa.